AstraZeneca Pharma India names Vinay Sharma as Business Unit Head
Bangalore: AstraZeneca Pharma India Limited has announced the appointment of Vinay Sharma as Business Unit Head - Rare Disease unit with effect from July 1, 2024.
"We wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr Vinay Sharma as Business Unit Head - Rare Disease unit with effect from July 1, 2024," the Company informed in a recent BSE filing.
Vinay Sharma is a Post‐Graduate in Marketing Management and Business Administration with over 23 years of rich industry experience. He joined AstraZeneca India in 2013 as Marketing Manager Diabetes. Over the last decade, years, he has held multiple sales, marketing, patient advocacy lead and leadership positions in AstraZeneca India and other international markets. He has been instrumental in leading the best-in-class launch of Forxiga in India. Currently, Mr. Vinay Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology.
Read also: CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal For Anti-cancer Drug Osimertinib
Medical Dialogues team had earlier reported that AstraZeneca Pharma India Limited and Mankind Pharma Limited had entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.
AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India. It is a listed company and is a subsidiary of AstraZeneca Plc, UK.
Next Story
